Chemotherapy for malignant pleural mesothelioma: past results and recent developments by Tomek, S et al.
Review
Chemotherapy for malignant pleural mesothelioma: past results
and recent developments
S Tomek*,1, S Emri
2, K Krejcy
3 and C Manegold
4
1Department of Medicine I, Clinical Division of Oncology, Vienna, Austria;
2Department of Chest Disease, Hacettepe University School of Medicine,
Ankara, Turkey;
3Eli Lilly Regional Operations GesmbH Area Medical Centre, Vienna, Austria;
4Clinical Division of Oncology, Department of Medicine,
Thoraxklinik Heidelberg, Germany
This review summarises the results of previously conducted clinical trials, and subsequently presents data arising from all phase II–III
studies on chemotherapy of malignant pleural mesothelioma (MPM) published since the last relevant overview. While response rates
exceeding 30% have barely been achieved with established cytotoxic drugs in MPM therapy, novel chemotherapeutic agents and their
combinations appear more promising. This applies especially to the antimetabolites, and in particular to pemetrexed that produced
response rates of up to 45% in combination with platinum compounds. Raltitrexed combined with oxaliplatin has also been shown to
be effective, and gemcitabine–applied as a single agent or in combination with cisplatin–as well as vinorelbine appear to improve the
quality of life in patients presenting with MPM. Data can now be more precisely analysed by increasingly implemented randomised
studies, applying a standardised staging system, and distinguishing prognostic groups. While chemotherapy for MPM remains a
challenging task, important steps have clearly been made in the past years to combat this aggressive disease. The publication of
pemetrexed with cisplatin phase III results in a peer-reviewed journal may soon establish a standard of care.
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Although MPM aetiology is well known, therapeutic success with
this disease has been unsatisfactory. Standard malignant pleural
mesothelioma (MPM) therapy is still deficient, and decisions for
surgical, radiotherapy or multimodal procedures are made on a
case-by-case basis. In the majority of cases, a palliative treatment
approach remains the only choice. The possibilities to resect MPM
curatively are rare and only given in early-stage disease. Yet even
at this point, resection is a matter of dispute because of historically
high morbidity and mortality rates, relapse tendencies and
disappointing long-term survival rates (Rusch and Venkatraman,
1996; Boutin et al, 1998). Irradiation for MPM assists in repelling
tumour growth and temporarily relieving pain, but not attaining
appreciably lengthened overall survival time (Kutcher et al, 1987;
Soubra et al, 1990; Bissett et al, 1991). There is also no clear
evidence that multimodality protocols involving surgery, radio-
therapy and chemotherapy can improve survival (Antman et al,
1980; Hilaris et al, 1984; Linden et al, 1996). Although success in
MPM chemotherapy has been limited, it now gives rise to promise
by the use of an established and standardised staging system, with
consideration given to prognostic factors and development of
novel cytostatic agents.
ROLE OF CHEMOTHERAPY
Chemotherapy for MPM continues to be challenging. A multitude
of cytotoxic drugs have been tested both as single agents and in
combination chemotherapy regimens. The rates of objective
tumour regression have only been between 10 and 30% with
cytotoxic monotherapy, having no significant impact on median
survival. Combination chemotherapy has shown no clear advan-
tage over single-agent therapy (Linden et al, 1996).
The evaluation of systemic chemotherapy in MPM has been
problematic for several reasons. Owing to the rarity of this disease,
only a few randomised studies based on large numbers of
participants have been implemented to provide statistically
significant statements regarding response to a particular therapy.
Furthermore, inadequate imaging procedures and nonuniform
staging systems have complicated data interpretation. As per-
formed in early studies, restaging by means of chest radiography
failed to determine response to a given therapy accurately.
Response rates have been more reliable since CT scanning has
been recognised as a diagnostic tool. In 1995, the International
Mesothelioma Interest Group (IMIG) proposed a novel TNM
staging system, which was designed to record data concerning the
natural history of the disease and was validated in two large
surgical series of mesothelioma patients (Rusch and Venkatraman,
1996; Pass et al, 1998). The universal application of this system has
ever since allowed for a more prudent evaluation of results
emerging from clinical studies (Pass et al, 1998; Steele and Rudd,
2000).
Early clinical trials of MPM patients included heterogeneous
groups of patients with divergent risk factors and were therefore
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particular treatment. In 1998, the European Organization for
Research and Treatment of Cancer (EORTC) identified several
prognostic variables for the course of the disease. In a multivariate
analysis of the EORTC, poor prognosis was associated with the
sarcomatous histologic subtype, male gender, poor performance
status and a high white blood cell count (Curran et al, 1998).
Likewise, the Cancer and Leukemia Group B (CALGB) analysed
several pretreatment factors pooled from seven phase II studies
that were predictive of poor survival and defined six prognostic
groups. Poor prognosis was seen in patients with the following
criteria: age older than 75 years, poor performance status, chest
pain, dyspnoea, weight loss, high white blood cell count, elevated
platelet count, low haemoglobin, elevated serum lactate dehydro-
genase levels, pleural effusion and nonepithelial histology.
Owing to the establishment of prognostic scoring systems,
identification of risk groups facilitated improved study design by
evaluating more homogeneous patient groups or risk-group
stratification in the course of randomisation (Curran et al, 1998).
The following sections summarise conventional single-agent and
combination chemotherapy strategies. Results emerging from
recent clinical studies with novel cytotoxic agents and their
combinations are then presented, which have been published since
the last review of chemotherapy in MPM.
Tables 1–3 summarise phase II–III single-agent and combina-
tion chemotherapy trials for MPM including more than 15
patients, which have been conducted since 1995.
Single-agent chemotherapy
Doxorubicin is the most frequently investigated chemotherapeutic
agent in the treatment of MPM. Studies have failed to corroborate
evidence, however, for encouraging response rates to doxorubicin
of up to 20% that had been reported in earlier studies (Aisner and
Wiernik, 1981; Antman and Corson, 1985). Likewise, newer
anthracyclines such as epirubicin, detorubicin, pirarubicin and
mitoxantrone have shown low levels of efficacy and have offered
no clinically relevant advantage over doxorubicin (Colbert et al,
1985; Eisenhauer et al, 1986; Sridhar et al, 1989; Kaukel et al, 1990;
Magri et al, 1991; van Breukelen et al, 1991; Mattson et al, 1992;
Magri et al, 1992). In summary, the overall response rate produced
by anthracyclines applied in MPM appears to be no higher than
15% and median survival does not exceed 8 months.
Apart from anthracyclines, several studies have investigated the
platinum compounds, cisplatin and carboplatin. Single-agent
cisplatin resulted in a response rate of merely 14.3% and a median
survival of 7.5 months (Zidar et al, 1988). Studies using the newer
compound carboplatin resulted in similar response rates ranging
between 6 and 16% (Mbidde et al, 1986; Raghavan et al, 1990;
Vogelzang et al, 1990).
The alkylating agents cyclophosphamide and mitomycin
have shown low-level activity in MPM therapy (Bajorin et al,
1987; Sorensen et al, 1985). Promising results initially arising
from high-dose ifosfamide therapy (Alberts et al, 1988) could not
be confirmed by subsequent studies (Falkson et al, 1992; Zidar
Table 1 Series of X15patients with MPM treated with single-agent chemotherapy since 1995
Single agent
First author
(year)
No. of
patients
Responders
95% confidence
interval (%)
Median survival
(months) No %
Anthracyclines and related compounds
Liposomal doxorubicin Baas (2000) 32 2 6 0–20 13
Liposomal doxorubicin Oh/ (2000) 24 0 0 na 9.3
Liposomal danaurubicin Steele (1998) 11 0 0 na 6.1
Platinum compounds
ZD0473 Giaccone (2001) 10 Two regressions of evaluable disease na na
Alkylating agents
Ifosfamide Andersen (1999) 26 1 4 0–11 10
Etoposide i.v. Sahmoud (1997) 49 2 4 1–15 7.3
Etoposide p.o. Sahmoud (1997) 45 3 7 2–20 9.5
Topoisomerase interactive agents
Campthotecin analogues
Irinotecan Kindler (2000) 28 0 0 10–55 7.9
Topotecan
Maksymiuk (1998) 22 0 0 na 8
Antimicrotubule agents
Vinca alcaloids
Vinorelbine Steele (2000) 64 12 21 10–44 13.4
Vincristine Martensson (1989) 23 0 0 0–14 7
Vinblastine Cowan (1988) 20 0 0 0–16 3
Taxanes
Docetaxel Belani (1999) 19 1 5 0–26 na
Docetaxel Vorobiof (2000) 22 3 14 7–46 12
Paclitaxel v. Meerbeck (1996) 25 0 0 0–15 9.8
Paclitaxel Vogelzang (1999) 35 Three regressions of evaluable disease 2–10 5
Antimetabolites
Edatrexate Kindler (1999) 20 5 25 9–49 9.6
Edatrexate+LV-rescue Kindler (1999) 38 6 16 6–31 6.6
Gemcitabine Kindler (2001) 17 0 0 3–13 4.1
Gemcitabine van Meerbeck (1999) 27 2 7 1–24 8
Gemcitabine Bischoff (1998) 16 5 31 na na
Pemetrexed Scagliotti (2001) 62 9 6 na 10.7
na=not applicable.
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The older vinca alkaloids vinblastine, vincristine and vindesine
have demonstrated no activity in the treatment of MPM
(Kelsen et al, 1983; Boutin et al, 1987; Cowan et al, 1988;
Martensson & Sorenson, 1989). Likewise, poor results were shown
with oral as well as IV etoposide (Tammilehto et al, 1994; Sahmoud
et al, 1997).
The antifolates methotrexate and edatrexate have been the only
single agents to produce comparatively better results. A Norwegian
study reported a satisfactory response rate of 37% for high-dose
methotrexate and a median survival of 11 months, for trial subjects
with an epithelial subtype drawing a particular benefit from this
chemotherapy option (Solheim et al, 1992). Sequential multicentre
phase II studies conducted by the CALGB have evaluated the
activity of the folate antagonist edatrexate, with and without
leucovorin rescue. Edatrexate produced 25% overall response rates
but proved to be relatively toxic. Leucovorin rescue in the control
arm led to decreased toxicities, but may also have reduced the
agent’s efficacy (Kindler et al, 1999). Other antimetabolites like
fluorouracil, dihydro-5-azacytidine (DHAC), dideazafolic acid and
trimetrexate have shown minor or no activity in the treatment of
Table 2 Series of X15 patients with MPM treated with combination chemotherapy since 1995
Responders
Agent First author (year) No. of patients No. % 95% confidence interval (%) Median survival
Doxorubicin-containing combinations
Doxorubicin+cisplatin+mitomycin Pennucci (1997) 23 5 21 7–42 11
Doxorubicin+cisplatin+mitomycin+bleomycin Breau (1991) 25 11 44 27–63 na
Cisplatin-containing combinations
Cisplatin+DHAC Samuels (1998) 29 5 17 5–30 6.4
Cisplatin+etoposide Eisenhauer (1988) 26 3 12 4–30 na
Cisplatin+gemcitabine Byrne (1999) 21 10 48 26–69 10.3
Cisplatin+gemcitabine Novak (2002) 52 17 33 20–46 11.2
Cisplatin+gemcitabine Van Haarst (2000) 22 4 15 na 10
Cisplatin+Irinotecan Nakano (1999) 15 4 27 8–55 7.1
Cisplatin+mitomycin+vinblastine Middleton (1998) 39 8 20 na 6
Cisplatin+pemetrexed (phase I) Thodtman (1999) 11 5 45 na na
Cisplatin+paclitaxel Fizazi (2000) 18 1 6 0–24 12
Other combinations
Methotrexate+mitoxantrone+mitomycin Pinto (2001) 22 6 32 12–51 13.5
Carboplatin+gemcitabine Aversa (1998) 18 3 16 na 8.6
Carboplatin+pemetrexed (phase I) Hughes (2002) 25 8 32 na 15
Oxaliplatin+raltitrexed Fizazi (2000) 30 9 30 15–49 na
Oxaliplatin+vinorelbine Steele (2000) 17 2 12 na na
Docetaxel+irinotecan Knuuttila (2000) 15 0 0 2–45 8.5
na=not applicable.
Table 3 Series of randomized phase II – III studies in patients with MPM treated with chemotherapy
Agent
First author
(year)
No. of
patients
Responders
95% confidence
interval (%)
Median
survival
(months) No. %
Doxorubicin vs cyclophosphamide Sorensen (1985) 32 0 0 0–19 na
00 0 – 1 9
Doxorubicin+cyclophosphamide vs doxorubicin+cyclophosphamide+DTIC Samson (1987) 76 4 11 6–21 7.5
5 13 6–21 6.3
Cisplatin+doxorubicin vs cisplatin+mitomycin Chahinian (1993) 70 5 14 5–30
5 26 12–43 7.7
Cisplatin+etoposide vs carboplatin White SC (2000) 25 1 8 na 4.7
0 0 5.4
Onconase vs doxorubicin Vogelzang (2000) 154 na na na 7.7
8.2
Cisplatin vs cisplatin+pemetrexed Vogelzang (2002) 456 na* na* na* na*
Ongoing trials agent No. of patients planned
Doxorubicin vs doxorubicin+onconase 300
Cisplatin vs cisplatin+raltitrexed 240
Pemetrexed vs best supportive care 240
Vinorelbine vs MVP vs best supportive care 840
Cisplatin+gemcitabine vs cisplatin+gemcitabine+bevacizumab 106
* Vogelzang N.: http://www.asco.org/asco/ascoMainConstructor/1,47468, 12|002351,00.asp?cat=General+Oncology.
na=not applicable.
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Combination chemotherapy
Doxorubicin-based regimens Doxorubicin is the anthracycline
most frequently included in chemotherapeutic regimens. Initially
encouraging response rates experienced with the doxorubicin–
cisplatin combination in two phase II studies carried out in Germany
(RR: 46%) and Italy (RR: 25%) (Henss et al, 1988; Ardizzoni et al,
1991) failed to be confirmed by a subsequent, randomised CALGB
study of doxorubicin–cisplatin vs mitomycin–cisplatin treatment
(Chahinian et al, 1993). The doxorubicin-cisplatin doublet was only
able to produce a 14% response rate and proved inferior to the
mitomycin–cisplatin combination (RR: 26%). Median survival
duration from study entry was 7.7 and 8.8 months, respectively,
with no significant differences between treatments. An Italian group
administered the triplet doxorubicin–cisplatin–mitomycin to 24
MPM patients and reported a response rate of 20.9%. Thus, the
observed level of activity was similar to that obtained with the
respective doublets (Pennucci et al,1 9 9 7 ) .
The combination of doxorubicin, cisplatin and cyclophospha-
mide was tested by another prospective trial and produced a
similar rate of response (Shin et al, 1995). A multi–institutional
randomised study was designed to compare the activity of
doxorubicin-cyclophosphamide with a triplet consisting of these
agents in addition to dacarbazine. With a response rate of 13%, the
triplet did not prove superior to the doublet (RR: 11%) (Samson
et al, 1987).
The combination of doxorubicin and ifosfamide has also been
investigated within two studies. One study giving doxorubicin and
ifosfamide every 3 weeks achieved a response rate of 12.5%
(Carmichael et al, 1989). Based on the same trial design, another
group applied dose-escalated doxorubicin at 75mgm
 2, with a
32% response rate (Dirix et al, 1994). However, the 7-month
median survival was poor and toxicity high, limiting the value of
this schedule in the treatment of MPM.
Disappointing response rates have also been shown by the
anthracyclines epirubicin and rubidazone as combined with
ifosfamide and dacarbazine (Zidar et al, 1983; Magri et al, 1992).
Cisplatin-based regimens Apart from combinations with anthra-
cyclines, cisplatin has also been tested in numerous other
chemotherapy regimens. Three trials evaluated cisplatin combined
with etoposide, showing response rates from 12 to 24%
(Eisenhauer et al, 1988; Planting et al, 1995; White et al, 2000).
The doublet combination of cisplatin and DHAC attained an
insufficient response rate of 17.3% (Samuels et al, 1998). Moderate
antitumour activity (RR: 25%) was achieved by the doublet
cisplatin–mitomycin in one arm of CALGB 8435, but median
survival was poor (7.7 months) (Chahinian et al, 1993). A 25%
response rate and a 13-month mean duration of response have
been indicated for the cisplatin–vinblastine combination (Tsa-
varis et al, 1994). The cisplatin–mitomycin-C–vinblastine triplet
did not prove to be superior to the doublets (RR: 23%), yet
produced a symptomatic benefit for 63% of the patients with
particularly good response for pain (Middleton et al, 1998).
Likewise, other treatments combining such conventional
cytotoxics as methotrexate with vincristine and mitomycin with
vindesine have failed to prove effective (Dimitrov et al, 1982;
Gridelli et al, 1992).
NOVEL CYTOTOXICS
Anthracyclines
Liposomal anthracyclines
Liposomal doxorubicin. Within a phase II study, the EORTC
treated 35 patients with liposomal doxorubicin (Caelyx
s)a ta
dosage of 45mgm
 2 every 4 weeks (Baas et al, 2000). The drug was
well tolerated, but the results were disappointing. Only two of the
31 patients (6%) showed a partial response and the median
survival was 13 months.
Similar results were reported by Oh et al, who administered
50mgm
 2 of liposomal doxorubicin (Doxil
s) every 4 weeks to 24
patients with pleural mesothelioma (Oh et al, 2000). With no
objective responses and a median survival of only 37 weeks, the
drug was considered inactive in this indication.
Liposomal daunorubicin. Liposomal daunorubicin (LD) was
given to 13 patients at 120mgm
 2 every 3 weeks, but no responses
were produced (Steele et al, 2001).
Platinum compounds
ZD0473
A phase II trial (Giaccone et al, 2001) assessed the efficacy of the
new generation platinum compound ZD0473 at 120mgm
 2 on day
1 of a 21-day cycle in mesothelioma patients that had relapsed after
previous platinum-based chemotherapy. Two of 10 (20%) patients,
experienced tumour shrinkage and five of 10 (50%) subjects had
stable disease.
Topoisomerase interactive agents
Camptothecin analogues
Irinotecan. The activity of single-agent irinotecan (125mgm
 2
given weekly for 4 weeks, every 6 weeks) in malignant
mesothelioma was investigated by the CALGB (Kindler et al,
2000). In 28 patients evaluable for analysis, no complete or partial
responses were observed and the median overall survival was 7.9
months, indicating that irinotecan, at least in this dose and
schedule, had no antitumor activity and considerable toxicity
(leucopenia, neutropenia, diarrhoea).
Furthermore, the combination of irinotecan and cisplatin was
evaluated by a Japanese group (Nakano et al, 1999). A total of 15
chemonaive MPM patients were treated with irinotecan at
60mgmg
 2 on days 1, 8 and 15 and cisplatin at 60mgm
 2 on
day 1, repeated every 28 days. A response rate of 26.7% (four
partial responses) was observed and the median survival after
chemotherapy was 28.3 weeks. In contrast to the trial conducted by
the CALGB, Nakano et al reported definite activity with only mild
toxicity of this combination regimen and concluded that it
warrants further clinical evaluation.
Recently, Verschraegen et al (2001) published retrospective data
of the same combination in 10 patients with peritoneal mesothe-
lioma. Six courses of irinotecan 50mgm
 2 (day 1, 8 and 15) and
cisplatin 50mgm
 2 (day 1) were administered every 4 weeks,
either intraperitoneally or intravenously, and were well tolerated.
The authors reported that 70% of the patients improved on
treatment. Owing to the observed clinical benefit, a phase II trial is
currently planned.
Topotecan. In order to evaluate the efficacy and toxicity of the
camptothecin analogue topotecan in the treatment of MPM, the
North Central Cancer Treatment Group treated 22 MPM patients
with topotecan 1.5mgm
 2 daily for 5 days at 3-week intervals. 18
patients (86%) experienced grade 3 or 4 neutropenia. There were
no objective responses seen and the median survival for all
patients was 230 days (Maksymiuk et al, 1998).
Antimicrotubule agents
Vinca alcaloids
Vinorelbine. Steele et al (2000) administered vinorelbine to 64
patients with MPM at a weekly 30mgm
 2 dose for 6 weeks. A
response rate of 21% (12 out of 64 patients) was observed and 63%
of patients experienced disease stabilisation. Furthermore, the
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The same study group conducted a trial to evaluate the activity
of vinorelbine at 30mgm
 2 on days 1 and 8 and oxaliplatin
130mgm
 2 on day 1 every 3 weeks in 21 MPM patients (Steele
et al, 2000). Only two partial responses had been observed and
toxicity had been significant. These inferior results could perhaps
result from the large number of stage IV patients, the higher
proportion of less favorable subtypes, and the inclusion of several
participants showing a low performance status. At any rate, the
addition of oxaliplatin to vinorelbine seems to bring no advantage,
thus discouraging further studies in this doublet.
Recently, a British randomised phase III study has been
initiated, comparing the efficacy of single-agent vinorelbine
(30mgm
 2 up to 60mgm
 2) vs MPV (mitomycin 8mgm
 2,
vinblastin 6mgm
 2, cisplatin 50mgm
 2) vs active best supportive
care alone.
Taxanes
Paclitaxel. A total of 25 patients with MPM were given paclitaxel
intravenously at a dose of 200mgm
 2 as a 3h infusion every 3
weeks in a phase II study conducted by the EORTC Lung Cancer
Cooperative Group (van Meerbeeck et al, 1996). No major
objective responses were seen and the median survival time was
only 39 weeks.
These disappointing results were confirmed by the CALGB,
which administered paclitaxel at a slightly higher dose of
250mgm
 2, given as a 24-hour infusion every 3 weeks plus
filgastrim (G-CSF) support to 35 patients with MPM (Vogelzang
et al, 1999). Only three (9%) regressions of evaluable disease were
observed and the median survival was 5 months.
Fizazi et al (2000) conducted a phase II study of paclitaxel
(200mgm
 2) and cisplatin (100mgm
 2), given to 18 patients on
day 1 every 3 weeks. With only one partial response and a response
rate of 6%, the paclitaxel–cisplatin doublet was considered
ineffective and the trial was stopped early.
Bednar (1999) evaluated the combination of paclitaxel at
175mgm
 2 and carboplatin at an AUC of 5–6 in seven patients
with malignant mesothelioma and reported more encouraging
results. One patient with peritoneal malignant mesothelioma had a
pathologically proven CR for a duration of 20 months. The overall
median survival was 15 months from diagnosis and 12 months
from the onset of treatment.
Docetaxel. The Eastern Cooperative Oncology Group assigned
19 patients with malignant mesothelioma to a phase II study of
docetaxel 100mgm
 2, administered every 21 days. Only one
patient achieved a partial response, with an overall response rate of
5%. The study group thus concluded that docetaxel was not effec-
tive in the treatment of malignant mesothelioma (Belani et al, 1999).
Vorobiof et al (2000), who also evaluated the activity of
docetaxel using the same treatment schedule, reported only three
partial remissions and six minor responses (25% or less reduction
in tumour burden) in 22 MPM patients with median survival
barely exceeding 12 months.
A clinical study further tested docetaxel at 60mgm
 2 in
combination with irinotecan at 190mgm
 2 on day 1 of a 3-weekly
cycle in 15 MPM patients (Knuuttila et al, 2000). No objective
responses were achieved, and median survival was 8.5 months
only. The study was finally discontinued owing to high toxicity and
deficient activity levels.
Antimetabolites
Antifolates
Raltitrexed. The EORTC has recently completed a phase II study
of the quinazoline antifolate raltitrexed (ZD1694, Tomudex) at
3mgm
 2 as a single agent in the treatment of malignant
mesothelioma, which is now in final analysis.
From 1999 to 2000, the Institut Gustave Roussy has treated 70
patients with a combination of raltitrexed (3mgm
 2) and
oxaliplatin (130mgm
 2). Preliminary results show an encouraging
response rate of 25% (14 of 57 patients evaluable for efficacy) and
acceptable toxicity (Fizazi et al, 2000).
Based on these promising results, the EORTC initiated a
randomised phase III study, evaluating the efficacy of the doublet
raltitrexed (3mgm
 2)– cisplatin (80mgm
 2) vs cisplatin
(80mgm
 2) alone.
Pemetrexed. A phase I study conducted in 1999 first investigated
the activity of the multitargeted antifolate pemetrexed (LY231514,
ALIMTA
s) combined with cisplatin in patients presenting with
solid tumours (Thodtmann et al, 1999). Of 11 mesothelioma
patients evaluable for analysis, five experienced a partial remission
(RR: 45%).
These promising data resulted in the largest phase III study ever
conducted in patients with MPM, which was initiated in March
1999. The results of this single-blind trial were first presented at
the ASCO annual meeting in May 2002. A total of 456 patients were
randomised to receive either cisplatin–pemetrexed (cisplatin
75mgm
 2 and pemetrexed 500mgm
 2 on day 1, every 21 days)
or cisplatin monotherapy in the control group. The combination of
pemetrexed–cisplatin resulted in superior median overall survival,
response rate, lung function and subjective quality-of-life mea-
sures (Vogelzang N http://www.asco.org/asco/ascoMainConstruc-
tor/1,47468,_12|002351,00.asp?cat¼General+Oncology). The prin-
cipal investigator concluded that based on these very promising
data, pemetrexed–cisplatin should now be considered standard
front–line therapy for patients with MPM.
Another phase I pemetrexed study demonstrated clinical activity
in combination with carboplatin. A total of 27 patients were treated
with various dose levels of pemetrexed and carboplatin on day 1 of
a 21-day schedule (Hughes et al, 2002). In 25 evaluable patients,
eight (32%) achieved a partial remmission and 14 experienced
stable disease at various dose levels. Furthermore, a symptomatic
improvement was documented in 19 cases.
A two-stage phase II trial has just been completed by Scagliotti
and collaborators, investigating single-agent pemetrexed in the
treatment of MPM. A total of 62 patients were given pemetrexed at
500mgm
 2 on day 1, every 3 weeks. Scagliotti et al (2001) reported
a response rate of 14.5% and a median survival of 10.7 months.
Furthermore, a randomised phase III trial comparing peme-
trexed plus best supportive care vs best supportive care alone in
previously treated patients with MPM is currently ongoing.
Nucleoside analogues
Gemcitabine. The activity of single-agent gemcitabine at
1250mgm
 2 on days 1, 8 and 15 on a 28-day schedule was
evaluated by the EORTC-Lung Cancer Group in 27 chemotherapy-
naive subjects with MPM (van Meerbeeck et al, 1999). Two partial
responses were achieved for an overall response rate of 7%. An
additional 56% experienced disease stabilisation and overall
median survival was 8 months.
The CALGB administered high-dose gemcitabine at
1500mgm
 2 on days 1, 8 and 15 in a 28-day cycle to 17
participants (Kindler et al, 2001). Only one minor regression and
six cases of stable disease were reported in 13 assessable patients,
with an overall median survival of 4.1 months. In contrast to these
data, Bischoff et al (1998) reported an encouraging response rate of
31% (5/16) with the same dose and schedule as the van Meerbeck
study (gemcitabine 1250mgm
 2 on days 1, 8 and 15, every 28
days). Furthermore, seven additional patients reported a symptom
relief via decreased pain or dyspnoea.
An Australian study group evaluated the doublet gemcitabine–
cisplatin in 21 patients presenting with advanced MPM (Byrne et al,
1999). The subjects received gemcitabine at 1000mgm
 2 on day 1,
8 and 15 and cisplatin at 100mgm
 2 on day 1 of a 28-day cycle.
This combination chemotherapy produced an encouraging
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Furthermore, nine of 10 responding patients experienced sig-
nificant relief of chest pain and dyspnoea. Subsequently, a
multicentre study was initiated, evaluating the same chemotherapy
regimen in 53 MPM patients (Novak et al, 2002). A response rate of
33% was achieved and the median survival time was 11.2 months.
Response to treatment was accompanied by significantly improved
global quality of life and respiratory function.
Contrary to the Australian trials, however, only four (15%) of 22
assessable subjects experienced a partial response within a
European multicentre phase II study (Van Haarst et al, 2000) of
gemcitabine at 1250mgm
 2 on days 1 and 8, in addition to
cisplatin at 80mgm
 2 on day 1. The discrepancy between these
studies may possibly result from the different treatment schedules,
patient selection criteria and methodology applied in treatment
evaluation.
In turn, Aversa et al (1998) on evaluated the activity of the
gemcitabine–carboplatin combination. A total of 20 patients were
given gemcitabine at 1000mgm
 2 on days 1, 8 and 15 and
carboplatin (AUC¼5) on day 1, every 28 days for a median
of 4.5 cycles. In 18 assessable subjects, a response rate of 16% and
an 8.6-month median survival rate was achieved.
Recently, investigators at the University of Chicago have
initiated a multicenter, randomised phase II trial of cisplatin–
gemcitabine and the vascular endothelial growth factor (VEGF)
inhibitor bevacizumab, which has shown preliminary evidence of
activity in MPM.
CONCLUSION
With rates of objective tumour regression ranging from 10 to 30%
for cytotoxic monotherapy, diffuse pleural mesothelioma was
considered to date to be widely chemoresistant. The most
favourable responses to conventional chemotherapeutic agents
were reported by the antimetabolites methotrexate and edatrexate.
In the past few years, a number of novel cytotoxic agents have
been introduced into clinical oncology, the activity of which has
also been tested in MPM therapy. Initial results produced by
monotherapy based on new antimetabolites, along with platin
combinations, provide encouragement. Preliminary results of the
raltitrexed–oxaliplatin combination have shown promising activ-
ity. Single-agent gemcitabine and the drug combined with cisplatin
appear to decrease symptoms associated with tumor load. In
particular, pemetrexed with cisplatin has demonstrated superior
median overall survival, response rate, lung function and quality-
of-life measures in the largest randomised trial in MPM. These
promising data suggest that finally effective chemotherapy exists
for this aggressive disease and that pemetrexed–cisplatin will
become a new systemic therapy standard.
REFERENCES
Aisner J, Wiernik PH (1981) Chemotherapy in the treatment of malignant
mesothelioma. Semin Oncol 8: 335–343
Alberts AS, Falkson G, Van Zyl L (1988) Malignant pleural mesothelioma:
phase II pilot study of ifosfamide and mesna. J Natl Cancer Inst 80:
698–700
Andersen MK, Krarup-Hansen A, Martensson G, Winther-Nielsen H,
Thylen A, Damgaard K, Olling S, Wallin J (1999) Ifosfamide in malignant
mesothelioma: a phase II study. Lung Cancer 24: 39–43
Antman KH, Blum RH, Greenberger JS, Flowerdew G, Skarin AT, Canellos
GP (1980) Multimodality therapy for malignant mesothelioma based on a
study of natural history. Am J Med 68: 356–362
Antman KH, Corson JM. (1985) Benign and malignant pleural mesothe-
lioma. Clin Chest Med 6: 127–140
Ardizzoni A, Rosso R, Salvati F, Fusco V, Cinquegrana A, De Palma M,
Serrano J, Pennucci MC, Soresi E, Crippa M et al (1991) Activity of
doxorubicin and cisplatin combination chemotherapy in patients with
diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task
Force (FONICAP) Phase II study. Cancer 67: 2984–2987
Aversa SL, Crcuri C, DePangher V et al (1998) Carboplatin and
Gemcitabine chemotherapy for malignant pleural mesothelioma
(MPM): A phase II study of the GSTPV. Ann of Oncol 9: 117
Baas P, van Meerbeeck J, Groen H, Schouwink H, Burgers S, Daamen S,
Giaccone G (2000) Caelyx in malignant mesothelioma: a phase II EORTC
study. Ann Oncol 11: 697–700
Bajorin D, Kelsen D, Mintzer DM (1987) Phase II trial of mitomycin in
malignant mesothelioma. Cancer Treat Rep 71: 857–858
Bednar ME, Chahinian P (1999) Paclitaxel and carboplatin for malignant
mesothelioma. Ann Meet Am Soc Clin Oncol A1916 18: 496a
Belani CP, Adak S, Aisner S, Stella PJ, Levitan N, Johnson DH (1999)
Docetaxel for malignant mesothelioma: phase II study of the eastern
Cooperative Oncology Group (ECOG 2595). Proc Am Soc Clin Oncol 1999
A1829, Vol 18, p.p. 474a
Bischoff HG, Manegold C, Knopp M, Blatter J, Drings P (1998) Gemcitabine
(Gemzar
s) may reduce tumor load and tumor associated symptoms in
malignant pleural mesothelioma. Proc Ann Meet Am Soc Clin Oncol 17;
A1784
Bissett D, Macbeth FR, Cram I (1991) The role of palliative radiotherapy in
malignant mesothelioma. Clin Oncol (R Coll Radiol) 3: 315–317
Boutin C, Irisson M, Guerin JC, Roegel E, Paramelle B, Brambilla C,
Jeannin L, Dabouis G, Le Caer H, Viallat JR (1987) Phase II trial
of vindesine in malignant pleural mesothelioma. Cancer Treat Rep 71:
205–206
Boutin C, Schlesser M, Frenay C, Astoul P (1998) Malignant pleural
mesothelioma. Eur Respir J 12: 972–981
Breau JL, Boaziz C, Morere JJF (1991) Cobination therapy with cisplatinum,
adramycin, bleomycin and mitomycin C plus systemic and intra-pleural
hyaluronidase in 25 consecitive cases of stages II, III pleural
mesothelioma. Presented at the first International Mesothelioma
Conference, Paris, France
Byrne MJ, Davidson JA, Musk AW, Dewar J, van Hazel G, Buck M,
de Klerk NH, Robinson BW (1999) Cisplatin and gemcitabine
treatment for malignant mesothelioma: a phase II study. J Clin Oncol
17: 25–30
Carmichael J, Cantwell BM, Harris AL (1989) A phase II trial of ifosfamide/
mesna with doxorubicin for malignant mesothelioma. Eur J Cancer Clin
Oncol 25: 911–912
Chahinian AP, Antman K, Goutsou M, Corson JM, Suzuki Y, Modeas C,
Herndon II JE, Aisner J, Ellison RR, Leone L et al (1993) Randomised
phase II trial of cisplatin with mitomycin or doxorubicin for malignant
mesothelioma by the Cancer and Leukemia Group B. J Clin Oncol 11:
1559–1565
Colbert N, Vannetzel JM, Izrael V, Schlienger M, Milleron B, Blanchon F,
Herman D, Akoun G, Roland J, Chatelet F et al (1985) A prospective
study of detorubicin in malignant mesothelioma. Cancer 56: 2170–2174
Cowan JD, Green S, Lucas J, Weick JK, Balcerzak SP, Rivkin SE, Coltman
CA, Baker LH (1988) Phase II trial of five day intravenous
infusion vinblastine sulfate in patients with diffuse malignant meso-
thelioma: a Southwest Oncology Group study. Invest New Drugs 6:
247–248
Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone
G (1998) Prognostic factors in patients with pleural mesothelioma: the
European Organization for Research and Treatment of Cancer experi-
ence. J Clin Oncol 16: 145–152
Dimitrov NV, Egner J, Balcueva E, Suhrland LG (1982) High-dose
methotrexate with citrovorum factor and vincristine in the treatment
of malignant mesothelioma. Cancer 50: 1245–1247
Dirix LY, van Meerbeeck J, Schrijvers D, Corthouts B, Prove A, van Marck
E, Vermeire P, van Oosterom AT (1994) A phase II trial of dose-escalated
doxorubicin and ifosfamide/mesna in patients with malignant mesothe-
lioma. Ann Oncol 5: 653–655
Eisenhauer EA, Evans WK, Murray N, Kocha W, Wierzbicki R, Wilson K
(1988) A phase II study of VP-16 and cisplatin in patients with
unresectable maignant mesothelioma. An NCI Canada Clinical Trials
Group Study. Invest New Drugs 6: 327–329
Chemotherapy for malignant pleural mesothelioma
S Tomek et al
172
British Journal of Cancer (2003) 88(2), 167–174 & 2003 Cancer Research UKEisenhauer EA, Evans WK, Raghavan D, Desmeules MJ, Murray NR, Stuart-
Harris R, Wilson KS (1986) Phase II study of mitoxantrone in patients
with mesothelioma: a National Cancer Institute of Canada Clinical Trials
Group Study. Cancer Treat Rep 70: 1029–1030
Falkson G, Hunt M, Borden EC, Hayes JA, Falkson CI, Smith TJ (1992) An
extended phase II trial of ifosfamide plus mesna in malignant
mesothelioma. Invest New Drugs 10: 337–343
Fizazi K, Caliandro R, Soulie P, Fandi A, Daniel C, Bedin A, Doubre H,
Viala J, Rodier J, Trandafir L, Le Chevalier T, Cvitkovic E, Armand J,
Ruffie P (2000) Combination raltitrexed (Tomudex(R))-oxaliplatin: a
step forward in the struggle against mesothelioma? The Institut Gustave
Roussy experience with chemotherapy and chemo-immunotherapy in
mesothelioma. Eur J Cancer 36: 1514–1521
Giaccone G, O’Brien M, Byrne MJ, Van Steenkiste J, Cosaert J (2001) Phase
II Trial of ZD0473 in Patients with Mesothelioma Relapsing After One
Prior Chemotherapy Regimen. Proc Ann. Meet Am Soc Clin Oncol A2781
20: 257b
Gridelli C, Pepe R, Airoma G, Incoronato P, Rossi A, Palazzolo G, Bianco
AR (1992) Mitomycin C and vindesine: an ineffective combination
chemotherapy in the treatment of malignant pleural mesothelioma.
Tumori 78: 380–382
Harvey VJ, Slevin ML, Ponder BA, Blackshaw AJ, Wrigley PF (1984)
Chemotherapy of diffuse malignant mesothelioma. Phase II trials of
single-agent 5-fluorouracil and adriamycin. Cancer 54: 961–964
Henss H, Fiebig HH, Schildge J, Arnold H, Hasse J (1988) Phase-II study
with the combination of cisplatin and doxorubicin in advanced
malignant mesothelioma of the pleura. Onkologie 11: 118–120
Hilaris BS, Nori D, Kwong E, Kutcher GJ, Martini N (1984) Pleurectomy
and intraoperative brachytherapy and postoperative radiation in the
treatment of malignant pleural mesothelioma. Int J Radiat Oncol Biol
Phys 10: 325–331
Hughes A, Calvert P, Azzabi A, Plummer A, Johnsons R, Rusthoven R,
Griffin M, Fishwick K, Boddy AV, Verril M, Calvert H (2002) Phase I
clinical and pharmacokinetic study of pemetrexed and carboplatin in
patients with malignant pleural mesothelioma. J Clin Oncology 20: 3533–
3544
Icli F, Karaoguz H, Hasturk S, Kurt B, Akbulut H, Dincol D, Demirkazik A,
Cay F, Akyar S (1996) Two dose levels of ifosfamide in malignant
mesothelioma. Lung Cancer 15: 207–213
Kaukel E, Koschel G, Gatzemeyer U, Salewski E (1990) A phase II study of
pirarubicin in malignant pleural mesothelioma. Cancer 66: 651–654
Kelsen D, Gralla R, Cheng E, Martini N (1983) Vindesine in the treatment of
malignant mesothelioma: a phase II study. Cancer Treat Rep 67: 821–822
Kindler HL, Belani CP, Herndon II JE, Vogelzang NJ, Suzuki Y, Green MR
(1999) Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or
without leucovorin rescue for malignant mesothelioma. Sequential phase
II trials by the cancer and leukemia group B. Cancer 86: 1985–1991
Kindler HL, Herndon JE, Vogelzang NJ, Green MR. (2000). CPT-11 in
Malignant Mesothelioma: A Phase II Trial by the Cancer and Leukemia
Group B (CALGB 9733). Proc Ann. Meet Am Soc Clin Oncol 27: A1978.
Vol. 19, pp. 505a
Kindler HL, Millard F, Herndon II JE, Vogelzang NJ, Suzuki Y, Green MR
(2001) Gemcitabine for malignant mesothelioma: A phase II trial by the
Cancer and Leukemia Group B. Lung Cancer 31: 311–317
Knuuttila A, Ollikainen T, Halme M, Mali P, Kivisaari L, Linnainmaa K,
Jekunen A, Mattson K (2000) Docetaxel and irinotecan (CPT-11) in the
treatment of malignant pleural mesothelioma–a feasibility study. Antic-
ancer Drugs 11: 257–261
Krarup-Hansen A (1996) Studies concerning high dose ifosfamide
to patients suffering from malignant mesothelioma. Lung Cancer 16:
101–102
Kutcher GJ, Kestler C, Greenblatt D, Brenner H, Hilaris BS, Nori D (1987)
Technique for external beam treatment for mesothelioma. Int J Radiat
Oncol Biol Phys 13: 1747–1752
Linden CJ, Mercke C, Albrechtsson U, Johansson L, Ewers SB (1996) Effect
of hemithorax irradiation alone or combined with doxorubicin and
cyclophosphamide in 47 pleural mesotheliomas: a nonrandomised phase
II study. Eur Respir J 9: 2565–2572
Magri MD, Foladore S, Veronesi A, Serra C, Nicotra M, Tommasi M, Grandi
G, Monfardini S, Bianchi C (1992) Treatment of malignant mesothelioma
with epirubicin and ifosfamide: a phase II cooperative study. Ann Oncol
3: 237–238
Magri MD, Veronesi A, Foladore S, De Giovanni D, Serra C, Crismancich F,
Tuveri G, Nicotra M, Tommasi M, Morassut S et al (1991) Epirubicin in
the treatment of malignant mesothelioma: a phase II cooperative study.
The North-Eastern Italian Oncology Group (GOCCNE)–Mesothelioma
Committee. Tumori 77: 49–51
Maksymiuk AW, Marschke Jr RF, Tazelaar HD, Grill J, Nair S, Marks RS,
Brooks BJ, Mailliard JA, Burton GM, Jett JR (1998) Phase II trial
of topotecan for the treatment of mesothelioma. Am J Clin Oncol 21:
610–613
Martensson G, Sorenson S (1989) A phase II study of vincristine in
malignant mesothelioma–a negative report. Cancer Chemother Pharma-
col 24: 133–134
Mattson K, Giaccone G, Kirkpatrick A, Evrard D, Tammilehto L, van
Breukelen FJ, Planteydt HT, van Zandwijk N (1992) Epirubicin in
malignant mesothelioma: a phase II study of the European Organization
for Research and Treatment of Cancer Lung Cancer Cooperative Group. J
Clin Oncol 10: 824–828
Mbidde EK, Harland SJ, Calvert AH, Smith IE (1986) Phase II trial of
carboplatin (JM8) in treatment of patients with malignant mesothelioma.
Cancer Chemother Pharmacol 18: 284–285
Middleton GW, Smith IE, O’Brien ME, Norton A, Hickish T, Priest K,
Spencer L, Ashley S. (1998) Good symptom relief with palliative MVP
(mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant
mesothelioma. Ann Oncol 9: 269–273
Nakano T, Chahinian AP, Shinjo M, Togawa N, Tonomura A, Miyake M,
Ninomiya K, Yamamoto T, Higashino K (1999) Cisplatin in combination
with irinotecan in the treatment of patients with malignant pleural
mesothelioma: a pilot phase II clinical trial and pharmacokinetic profile.
Cancer 85: 2375–2384
Novak A, Byrne M, Williamson R (2002) Multicentre phase II study of
cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 87:
491–496
Oh Y, Perez-Soler R, Fossella FV, Glisson BS, Kurie J, Walsh GL, Truong M,
Shin DM (2000) Phase II study of intravenous Doxil in malignant pleural
mesothelioma. Invest New Drugs 18: 243–245
Pass HI, Temeck BK, Kranda K, Steinberg SM, Feuerstein IR (1998)
Preoperative tumor volume is associated with outcome in malignant
pleural mesothelioma. J Thorac Cardiovasc Surg 115: 310–317 discussion
317–318
Pennucci MC, Ardizzoni A, Pronzato P, Fioretti M, Lanfranco C, Verna A,
Giorgi G, Vigani A, Frola C, Rosso R (1997) Combined cisplatin,
doxorubicin, and mitomycin for the treatment of advanced pleural
mesothelioma: a phase II FONICAP trial. Italian Lung Cancer Task Force.
Cancer 79: 1897–1902
Pinto C, Marino A, Guaraldi M, Melotti B, Piana E, Martoni A, Pannuti F
(2001) Combination chemotherapy with mitoxantrone, methotrexate,
and mitomycin (MMM regimen) in malignant pleural mesothelioma: a
phase II study. Am J Clin Oncol 24(2): 143–147
Planting AS, van der Burg ME, Goey SH, Schellens JH, van den Bent MJ, de
Boer-Dennert M, Stoter G, Verweij J (1995) Phase II study of a short
course of weekly high-dose cisplatin combined with long-term oral
etoposide in pleural mesothelioma. Ann Oncol 6: 613–615
Raghavan D, Gianoutsos P, Bishop J, Lee J, Young I, Corte P, Bye P,
McCaughan B (1990) Phase II trial of carboplatin in the management of
malignant mesothelioma. J Clin Oncol 8: 151–154
Rusch VW, Venkatraman E (1996) The importance of surgical staging in
the treatment of malignant pleural mesothelioma. J Thorac Cardiovasc
Surg 111: 815–825 discussion 825–826
Sahmoud T, Postmus PE, van Pottelsberghe C, Mattson K, Tammilehto L,
Splinter TA, Planting AS, Sutedja T, van Pawel J, van Zandwijk N, Baas P,
Roozendaal KJ, Schrijver M, Kirkpatrick A, Van Glabbeke M, Ardizzoni
A, Giaccone G (1997) Etoposide in malignant pleural mesothelioma: two
phase II trials of the EORTC Lung Cancer Cooperative Group. Eur
J Cancer 33: 2211–2215
Samson MK, Wasser LP, Borden EC, Wanebo HJ, Creech RH, Phillips M,
Baker LH (1987) Randomised comparison of cyclophosphamide,
imidazole carboxamide, and adriamycin versus cyclophosphamide and
adriamycin in patients with advanced stage malignant mesothelioma: a
Sarcoma Intergroup Study. J Clin Oncol 5: 86–91
Samuels BL, Herndon II JE, Harmon DC, Carey R, Aisner J, Corson JM,
Suzuki Y, Green MR, Vogelzang NJ (1998) Dihydro-5-azacytidine
and cisplatin in the treatment of malignant mesothelioma: a
phase II study by the Cancer and Leukemia Group B. Cancer 82:
1578–1584
Scagliotti G, Shin D, Kindler H, Johnson D, Keppler U (2001) Phase II
Study of ALIMTA (pemetrexed disodium, MTA) Single Agent in
Patients with Malignant Pleural Mesothelioma. Eur J Cancer 37
(Suppl. 6): 20
Chemotherapy for malignant pleural mesothelioma
S Tomek et al
173
British Journal of Cancer (2003) 88(2), 167–174 & 2003 Cancer Research UKShin DM, Fossella FV, Umsawasdi T, Murphy WK, Chasen MH, Walsh G,
Komaki R, McMurtrey MJ, Hong WK (1995) Prospective study of
combination chemotherapy with cyclophosphamide, doxorubicin, and
cisplatin for unresectable or metastatic malignant pleural mesothelioma.
Cancer 76: 2230–2236
Solheim OP, Saeter G, Finnanger AM, Stenwig AE (1992) High-dose
methotrexate in the treatment of malignant mesothelioma of the pleura.
A phase II study. Br J Cancer 65: 956–960
Sorensen PG, Bach F, Bork E, Hansen HH (1985) Randomised trial of
doxorubicin versus cyclophosphamide in diffuse malignant pleural
mesothelioma. Cancer Treat Rep 69: 1431–1432
Soubra M, Dunscombe PB, Hodson DI, Wong G (1990) Physical aspects of
external beam radiotherapy for the treatment of malignant pleural
mesothelioma. Int J Radiat Oncol Biol Phys 18: 1521–1527
Sridhar KS, Hussein AM, Feun LG, Zubrod CG (1989) Activity of
pirarubicin (40-0-tetrahydropyranyladriamycin) in malignant mesothe-
lioma. Cancer, 63: 1084–1091
Steele JP, O’Doherty CA, Shamash J, Evans MT, Gower NH, Tischkowitz
MD, Rudd RM (2001) Phase II trial of liposomal daunorubicin in
malignant pleural mesothelioma. Ann Oncol 12: 497–499
Steele JP, Rudd RM (2000) Malignant mesothelioma: predictors of
prognosis and clinical trials. Thorax 55: 725–726
Steele JP, Shamash J, Evans MT, Gower NH, Tischkowitz MD, Rudd RM
(2000) Phase II study of vinorelbine in patients with malignant pleural
mesothelioma. J Clin Oncol 18: 3912–3917
Tammilehto L, Maasilta P, Mantyla M, Salo J, Mattson K (1994) Oral
etoposide in the treatment of malignant mesothelioma. A phase II study.
Ann Oncol 5: 949–950
Thodtmann R, Depenbrock H, Blatter J, Johnson RD, van Oosterom A,
Hanauske AR (1999) Preliminary results of a phase I study with MTA
(LY231514) in combination with cisplatin in patients with solid tumors.
Semin Oncol 26: 89–93
Tsavaris N, Mylonakis N, Karvounis N, Bacoyiannis C, Briasoulis E, Skarlos
D, Pavlidis N, Stamatelos G, Kosmidis P (1994) Combination
chemotherapy with cisplatin-vinblastine in malignant mesothelioma.
Lung Cancer 11: 299–303
van Breukelen FJ, Mattson K, Giaccone G, van Zandwijk N, Planteydt HT,
Kirkpatrick A, Dalesio O (1991) Mitoxantrone in malignant pleural
mesothelioma: a study by the EORTC Lung Cancer Cooperative Group.
Eur J Cancer 27: 1627–1629
Van Haarst JW, Burgers JA, Manegold CH et al (2000) Multicenter phase II
study of gemcitabine and cisplatin in malignant pleural mesothelioma
(MPM). Program and abstracts of the 9th World Conference on Lung
Cancer; September 11–15, Tokyo, Japan. Abstract 56
van Meerbeeck JP, Baas P, Debruyne C, Groen HJ, Manegold C, Ardizzoni
A, Gridelli C, van Marck EA, Lentz M, Giaccone G (1999) A Phase II
study of gemcitabine in patients with malignant pleural mesothelioma.
European Organization for Research and Treatment of Cancer Lung
Cancer Cooperative Group. Cancer 85: 2577–2582
van Meerbeeck J, Debruyne C, van Zandwijk N, Postmus PE, Pennucci MC,
van Breukelen F, Galdermans D, Groen H, Pinson P, van Glabbeke M,
van Marck E, Giaccone G (1996) Paclitaxel for malignant pleural
mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative
Group. Br J Cancer 74: 961–963
Verschraegen C, Le D, Kudelka A, Kavanagh J, Hunt K (2001) Cisplatin and
Irinotecan (CPT-11) for Peritoneal Mesothelioma. Proc Ann Meet Am Soc
Clin Oncol A2110 20: 90
Vogelzang NJ, Goutsou M, Corson JM, Suzuki Y, Graziano S, Aisner J,
Cooper MR, Coughlin KM, Green MR (1990) Carboplatin in malignant
mesothelioma: a phase II study of the Cancer and Leukemia Group B.
Cancer Chemother Pharmacol 27: 239–242
Vogelzang NJ, Herndon II JE, Cirrincione C, Harmon DC, Antman KH,
Corson JM, Suzuki Y, Citron ML, Green MR (1997) Dihydro-5-
azacytidine in malignant mesothelioma. A phase II trial demonstrating
activity accompanied by cardiac toxicity. Cancer and Leukemia Group B.
Cancer 79: 2237–2242
Vogelzang NJ, Herndon II JE, Miller A, Strauss G, Clamon G, Stewart FM,
Aisner J, Lyss A, Cooper MR, Suzuki Y, Green MR (1999) High-dose
paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II
study 9234. Ann Oncol 10: 597–600
Vogelzang NJ, Weissman LB, Herndon II JE, Antman KH, Cooper MR,
Corson JM, Green MR (1994) Trimetrexate in malignant mesothelioma:
A Cancer and Leukemia Group B Phase II study. J Clin Oncol 12: 1436–
1442
Vorobiof DA, Chasen MR, Abratt R, Rapoport B, Cronje N, Fourie L,
McMichael G, Hacking D (2000) Taxotere in malignant pleural
mesothelioma. A Phase II clinical trial. Program and abstracts of the
9th World Conference on Lung Cancer; September 11–15, Tokyo, Japan.
Abstract 58.
White SC, Anderson H, Jayson GC, Ashcroft L, Ranson M, Thatcher N
(2000) Randomised phase II study of cisplatin-etoposide versus
infusional carboplatin in dvanced non-small-cell lung cancer and
mesothelioma. Ann Oncol 11: 201–206
Zidar BL, Benjamin RS, Frank J, Lane M, Baker LH (1983) Combination
chemotherapy for advanced sarcomas of bone and mesothelioma
utilizing rubidazone and DTIC: a Southwest Oncology Group Study.
Am J Clin Oncol 6: 71–74
Zidar BL, Green S, Pierce HI, Roach RW, Balcerzak SP, Militello L (1988) A
phase II evaluation of cisplatin in unresectable diffuse malignant meso-
thelioma: a Southwest Oncology Group Study. Invest New Drugs 6: 223–226
Zidar BL, Metch B, Balcerzak SP, Pierce HI, Militello L, Keppen MD,
Berenberg JL (1992) A phase II evaluation of ifosfamide and mesna in
unresectable diffuse malignant mesothelioma. A Southwest Oncology
Group study. Cancer 70: 2547–2551
Chemotherapy for malignant pleural mesothelioma
S Tomek et al
174
British Journal of Cancer (2003) 88(2), 167–174 & 2003 Cancer Research UK